A Study to Learn About Novel Hormonal Therapies (NHTs) for Metastatic Castration-sensitive Prostate Cancer (mCSPC) in People Who Were in the Armed Forces
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
With
Astellas Pharma Inc
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Male with ≥ 1 diagnosis claim for prostate cancer
Had documented secondary metastasis code on or after the initial prostate cancer diagnosis
Had initiated novel hormonal therapy (abiraterone, apalutamide, or enzalutamide) within 90 days prior to the metastasis date or on or after the metastasis date. The initiation date of the earliest novel hormonal therapy will be defined as the index date
≥18 years old on index date
Continuous enrollment for at least 365 days before index date
Evidence to be castration-sensitive:
* No prior surgical castration any time prior to the index date or no medical castration with ≥8 weeks of continuous use within -90 to -365 days prior to the index date, OR
* Diagnosis of hormone sensitive malignancy status within 90 days before the index date
You may not be if
Evidence of castration-resistance prior to the index date
* Received other prostate cancer treatment including NHT, non-steroidal anti-androgen (NSAA), chemotherapy, immunotherapy, radium 223, lutetium Lu 177 vipivotide tetraxetan, ketoconazole, or PARP inhibitor prior to the index date
* Had diagnosis code indicating hormone resistance prior to the index date
* A rise in prostate-specific antigen from the nadir by ≥2 ng/mL after castration
Had a prior history of other cancers (except non-melanoma skin cancer)
Participation in a clinical trial during the 30 days before the index date
